Sigal Arad - Enlivex Therapeutics Director HR
| ENLV Stock | USD 1.14 0.07 6.54% |
Insider
Sigal Arad is Director HR of Enlivex Therapeutics
| Address | 14 Einstein Street, Ness Ziona, Israel, 7403618 |
| Phone | 972 2 670 8072 |
| Web | https://www.enlivex.com |
Enlivex Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.2746) % which means that it has lost $0.2746 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6117) %, meaning that it created substantial loss on money invested by shareholders. Enlivex Therapeutics' management efficiency ratios could be used to measure how well Enlivex Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.83 in 2024. Return On Capital Employed is likely to drop to -1 in 2024. At this time, Enlivex Therapeutics' Non Current Assets Total are fairly stable compared to the past year. Non Currrent Assets Other is likely to climb to about 187.9 K in 2024, whereas Total Assets are likely to drop slightly above 30.6 M in 2024.Similar Executives
| Showing other executives | INSIDER Age | ||
| Jonathan Siegal | Vericel Corp Ord | N/A | |
| CPA CPA | BioLineRx | 48 | |
| Eran CPA | Collplant Biotechnologies | 56 | |
| Jennifer Lachey | Keros Therapeutics | 51 | |
| Abi MD | BioLineRx | 47 | |
| Raziel Fried | BioLineRx | N/A | |
| Liron MBA | BioLineRx | N/A | |
| Dr MedSc | Phio Pharmaceuticals Corp | 68 | |
| Sven MD | Merus BV | 61 | |
| Simon MBBS | Keros Therapeutics | 54 | |
| Eyal MBA | Protalix Biotherapeutics | 48 | |
| Gregory Russotti | Century Therapeutics | 57 | |
| Jillian Connell | Merus BV | N/A | |
| Ido Morpurgo | Purple Biotech | 51 | |
| Jael MSc | BioLineRx | N/A | |
| Advocate Kotler | BioLineRx | 72 | |
| Hennie Hoogenboom | Merus BV | N/A | |
| Keith MBA | Keros Therapeutics | 54 | |
| Mark Wallet | Century Therapeutics | N/A | |
| III CFA | Checkpoint Therapeutics | 46 | |
| Richard MD | Corvus Pharmaceuticals | 73 | |
Management Performance
| Return On Equity | -0.61 | ||||
| Return On Asset | -0.27 |
Enlivex Therapeutics Leadership Team
Elected by the shareholders, the Enlivex Therapeutics' board of directors comprises two types of representatives: Enlivex Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Enlivex. The board's role is to monitor Enlivex Therapeutics' management team and ensure that shareholders' interests are well served. Enlivex Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Enlivex Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Veronique AmorBaroukh, Senior Operations | ||
| Shachar CPA, Chief Officer | ||
| Oren Hershkovitz, Chief Officer | ||
| Sigal Arad, Director HR | ||
| Shai MBA, Executive Chairman | ||
| Pr MD, Founder Officer |
Enlivex Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Enlivex Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.61 | ||||
| Return On Asset | -0.27 | ||||
| Current Valuation | (704.12 K) | ||||
| Shares Outstanding | 21.41 M | ||||
| Shares Owned By Insiders | 5.73 % | ||||
| Shares Owned By Institutions | 18.80 % | ||||
| Number Of Shares Shorted | 99.23 K | ||||
| Price To Earning | (11.97) X | ||||
| Price To Book | 0.85 X | ||||
| EBITDA | (28.22 M) |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Enlivex Stock Analysis
When running Enlivex Therapeutics' price analysis, check to measure Enlivex Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Enlivex Therapeutics is operating at the current time. Most of Enlivex Therapeutics' value examination focuses on studying past and present price action to predict the probability of Enlivex Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Enlivex Therapeutics' price. Additionally, you may evaluate how the addition of Enlivex Therapeutics to your portfolios can decrease your overall portfolio volatility.